Medovate partners with New York School of Regional Anesthesia to support launch of new technology for regional anaesthesia


03-06-2020
Statue of Liberty

Medovate, the medical device development company, has announced that it will be partnering with the New York School of Regional Anesthesia (NYSORA) to support the launch of SAFIRA™,  its innovation for regional anesthesia in the United States.
 

SAFIRA™ (SAFer Injection for Regional Anesthesia) is an FDA approved revolutionary new technology that transforms regional anesthesia into a one person procedure, putting control in the hands of the anesthesiologist. A unique safety solution monitors and limits injection pressure. This helps to improve patient safety by reducing the risk of patient nerve damage resulting from accidental intraneural injection.

Developed in collaboration with anesthesiologists in the UK National Health Service (NHS), Medovate is launching this game changing technology initially in the United States. Three US-based companies have already signed agreements to act as exclusive distributors for the innovative medical technology.

Chris Rogers, Sales and Marketing Director at Medovate, commented: "Medovate are delighted to be working with NYSORA. We believe they are a great fit for us to help position the unique benefits in patient safety and cost optimization that SAFIRA™ will provide to anesthesiologists across the United States. We are looking forward to building a close relationship as SAFIRA™ is launched in the coming weeks”.

Prof. Dr. Admir Hadžić, M.D., PhD, President, NYSORA commented: “Being at the forefront of the developments in regional anesthesia for nearly 3 decades, NYSORA has always supported improvements in technology and safety in regional anesthesia. With COVID-19 pandemic, nerve blocks have emerged as the anesthesia of choice for emergency extremity surgery and a modality that can help re-establish elective orthopedic outpatient surgery programs. We are delighted to partner with MEDOVATE and their milestone development in remote-controlled local anesthetic administration and injection pressure monitoring systems for more efficient and safer practice of nerve blocks”.

Amid the current COVID-19 pandemic, regional anaesthesia is recommended as the anesthetic method of choice for surgery for suspected or confirmed COVID-19 patients. Regional anaesthesia obviates the need for mechanical ventilation, preserves respiratory function and decreases virus aerosolization and potential for viral transmission. Moreover, with the increasing shift toward same-day surgery across USA, regional anesthesia has become the must-have component of multimodal perioperative management in many patients.

 

Medovate is a medical device company dedicated to the development and commercialisation of innovative medical technologies created within the NHS and beyond to improve patient care.

Medovate Ltd